Thermo Fisher Scientific Inc.
Close on Nov 2, 2026Market cap $252.41BP/E 36.0Yield 0.25%
Thermo Fisher Scientific Segment Income by Year
Segment Income — Laboratory Products & Biopharma Services ($M)
Thermo Fisher Scientific Segment Income: $3,350M in FY2025, up 8.4% from a year earlier.
Where the FY2025 figure comes from
“LPBS: Segment income 731 825 868 925 3,350 778 936 1,067”
Source: Q3 2026 Reconciliation of Financial Information ↗
Full breakdown of external/intersegment revenues, Cost of Revenues, SG&A, R&D, Operating Assets (AR + Inventory), CapEx, and Depreciation under the new ASU 2023-07 accounting standard.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Segment Income — Laboratory Products & Biopharma Services ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3,350 | +8.4% | Q3 2026 Reconciliation of Financial Information ↗ |
| FY2024 | Dec 31, 2024 | 3,090 | -8.0% | Q4 & FY2025 Reconciliation of Financial Information ↗ |
| FY2023 | Dec 31, 2023 | 3,358 | +16.9% | Q4 & FY2024 Reconciliation of Financial Information ↗ |
| FY2022 | Dec 31, 2022 | 2,872 | – | SEC Form 8-K (8k_2023Q4, filed 2024-01-31) ↗ |
Breakdown
What makes up segment Income
- Segment Income Margin — Laboratory Products & Biopharma Services14.0% · FY2025
- Margin Expansion (percentage points) — Laboratory Products & Biopharma Services0.7% · FY2025
- Doanh thu khách hàng bên ngoài (External Customer Revenues — Note 11) — Laboratory Products & Biopharma Services23,818 · FY2025
- Intersegment Revenues — Note 11 — Laboratory Products & Biopharma Services167 · FY2025
- Segment Cost of Revenues — ASU 2023-07 — Laboratory Products & Biopharma Services18,609 · FY2025
- Segment SG&A — ASU 2023-07 — Laboratory Products & Biopharma Services2,392 · FY2025
- Segment R&D Expense — ASU 2023-07 — Laboratory Products & Biopharma Services56 · FY2025
- Segment Assets: AR + Inventory — Laboratory Products & Biopharma Services6,485 · FY2025
- Segment Purchases of PP&E — Laboratory Products & Biopharma Services1,005 · FY2025
- Segment Depreciation — Laboratory Products & Biopharma Services604 · FY2025
- Goodwill — Laboratory Products & Biopharma Services24,232 · FY2025
Cite this data
StockData. (2026). Thermo Fisher Scientific Segment Income ($M), annual FY2022–FY2025 [Data set]. Compiled from Thermo Fisher Scientific SEC filings and investor materials. https://stockdatahq.com/stocks/tmo/kpis/seg-income-lpbs
See every metric in the Thermo Fisher Scientific KPI table. Data updated Oct 29, 2026.